Up to 47.9% of Asian NSCLC patients harbour EGFR mutation.2, 3 Fusion of the Echinoderm microtubule‐associated protein like‐4 (EML4) and anaplastic lymphoma kinase (ALK) represent another distinct mechanism of driver mutation in NSCLC, accounting for about 4%‐8.1% patients.4, 5 Although chemotherapy remains the main treatment of advanced NSCLC, small molecular tyrosine kinase inhibitors (TKIs) were recommended as the first‐line treatment of advanced NSCLC with druggable driver mutations. The gene discussed is ALK; the disease is non-small cell lung carcinoma.